Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
基本信息
- 批准号:10506915
- 负责人:
- 金额:$ 2.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptionAffinity ChromatographyAlabamaAntibodiesArtificial MembranesBindingBiological AssayBuffersCell membraneCell physiologyCellsCellular AssayCellular MembraneCharacteristicsChemicalsChemistryColumn ChromatographyComplexComplex MixturesConsumptionDataData AnalysesDevelopmentDiabetes MellitusDialysis procedureDrug TargetingEnzymesFishesG-Protein-Coupled ReceptorsGoalsImmobilizationIndividualIntegral Membrane ProteinIon ChannelLaboratoriesLeadLibrariesLigandsMalignant NeoplasmsMembrane ProteinsMethodologyMethodsModernizationNational Center for Complementary and Integrative HealthNatural Product DrugNatural ProductsNatureNeurodegenerative DisordersNeurotrophic Tyrosine Kinase Receptor Type 2Particle SizePerformancePharmaceutical PreparationsPharmacodynamicsPharmacologic SubstancePharmacologyPhasePhytochemicalPlant ExtractsPreparationProceduresProcessPropertyProtein Tyrosine KinaseProteinsProtocols documentationResearchResearch PersonnelResourcesSamplingSmokeSolidSourceSpeedSurfaceTechniquesTechnologyTemperatureTestingTimeUniversitiesValidationbasechronic paincommercializationcostdesigndrug candidatedrug discoveryhigh throughput screeningimprovedinnovationinterestnew technologynovelnovel strategiesnovel therapeuticsparticlepressurepreventprogramsreceptorscaffoldscreeningtool
项目摘要
Project Summary
Natural products are a rich source of pharmacologically active compounds. However, due to technical constrains
the currently used high-throughput screening techniques are not compatible with complex natural samples. One
of the greatest challenges in the identification of new drug leads from natural products is the complexity of the
extracts, that requires enormous amount of time and effort to discover biologically active secondary metabolites.
Traditional screening methods often require isolation of individual compounds from mixtures through chemical
separation, followed by derepliction and assay analysis, which are time consuming, labor intensive, and costly.
High throughput screening techniques mainly focus on synthetic libraries of individual compounds and are not
compatible with mixtures. In contrast, protein target immobilization techniques can directly fish out binding
compounds eliminating the need to isolate individual compounds. Unfortunately, most of the protein
immobilization methodologies suffer from significant non-specific binding of compounds to support surfaces,
which makes them not suitable for screening complex mixtures. In addition, the majority of the immobilized target
proteins on solid surfaces are currently limited to cytosolic proteins, such as enzymes or antibodies. This is a
great limitation, because over 50% of all modern pharmaceuticals use membrane proteins as prime targets.
Cellular membrane affinity chromatography (CMAC) is an approach that allows for the identification of
compounds, present in complex matrices and specifically interacting with the immobilized transmembrane
protein. CMAC columns have proven to be useful in screening plant extracts and smoke condensates for new
ligands targeting different classes of transmembrane proteins. However, one of the challenges that prevents
CMAC from wider use is the relatively complex preparation protocol of CMAC columns and the lack of easy-to-
use catch and release chromatographic kits. We propose the development of a novel and patentable CMAC kit
with an optimized preparation protocol of CMAC columns. Using this novel approach homogenized cell
membrane fragments with the targeted proteins will be immobilized on IAM.PC.DD2 columns, produced solely
by Regis Technologies. The immobilization step using pre-packed columns eliminates the need for solubilization
and dialysis steps used in the current protocol. The newly developed CMAC kit will speed up the identification of
phytochemicals targeting transmembrane proteins. This novel assay will be ideally suited to build libraries of
pharmacologically active natural compounds that further might be tested using modern screening platforms.
CMAC is also a tool that can replace functional cell-based assays in determining certain pharmacodynamic
properties of drug candidates, for example: Kd (the concentration of drug that binds 50% of the receptors). The
CMAC kit can easily be applied in drug discovery laboratories to identify novel drug templates that can be further
used to treat certain forms of cancer, neurodegenerative diseases, chronic pain, diabetes and many other
illnesses.
项目总结
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
细胞膜亲和层析柱鉴定与固定化原肌球蛋白激酶受体 B 相互作用的特殊植物代谢物
- DOI:10.3791/63118
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Arituluk, Zekiye Ceren;Adhikari, Bishnu;Maitra, Urmila;Goodman, Caroline;Ciesla, Lukasz M.
- 通讯作者:Ciesla, Lukasz M.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lukasz Michal Ciesla其他文献
Lukasz Michal Ciesla的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lukasz Michal Ciesla', 18)}}的其他基金
Centella asiatica effects on neuroinflammatory responses in Drosophila models of acute inflammation and aging
积雪草对果蝇急性炎症和衰老模型神经炎症反应的影响
- 批准号:
10415346 - 财政年份:2022
- 资助金额:
$ 2.68万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 2.68万 - 项目类别:
相似国自然基金
去乙酰化酶SIRT5缺乏通过增强VDAC1乙酰化和二聚化加速脊髓损伤后血脊髓屏障破坏的机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
丁酸钠联合铁死亡诱导剂RSL3通过调节肠道菌群抑制结直肠癌的机制研究
- 批准号:JCZRLH202501293
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
靶向PAQR3通过调控心肌线粒体自噬改善压力超负荷诱导心衰的机制研究
- 批准号:JCZRLH202500922
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
SHCBP1通过KIF11调控线粒体自噬促进肺腺癌顺铂耐药的机制研究
- 批准号:JCZRYB202500506
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
TAMs外泌体源LncRNA GHET1通过HSP70调控胃癌细胞EMT促进顺铂耐药的机制研究
- 批准号:JCZRYB202500668
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
HABP4通过FMRP/MAP1B通路调控肠神经系统发育的作用及机制研究
- 批准号:JCZRYB202500700
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
胆碱激酶B失活变异通过抑制线粒体功能促进扩张型心肌病的机制研究
- 批准号:JCZRYB202500709
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
分子伴侣Hsp90/FKBP51复合物通过稳定PPARγ减轻糖尿病心缺血再灌注损伤的机制研究
- 批准号:JCZRYB202500986
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
RNA结合蛋白hnRNPD通过调控与细胞死亡相关基因MAP4K4的可变剪接介导的细胞周期调控促进肾母细胞瘤细胞增殖的机制研究
- 批准号:JCZRYB202501327
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
黄连外用液通过抑制肺炎克雷伯杆菌生物膜的形成治疗手术切口 感染的机制
- 批准号:JCZRLH202500158
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 2.68万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 2.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 2.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 2.68万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 2.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 2.68万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 2.68万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 2.68万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 2.68万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 2.68万 - 项目类别:
Standard Grant